Protective effect of betaine on changes in the levels of lysosomal enzyme activities in heart tissue in isoprenaline-induced myocardial infarction in Wistar rats.
Myocardial infarction is one of the most common manifestations of cardiovascular disease. In the present study, we investigated the protective effect of betaine, a potent lipotropic molecule, on changes in the levels of lysosomal enzymes and lipid peroxidation in isoprenaline-induced myocardial infarction in Wistar rats, an animal model of myocardial infarction in man. Male albino Wistar rats were pretreated with betaine (250 mg/kg body weight) daily for a period of 30 days. After the treatment period, isoprenaline (11 mg/100 g body weight) was intraperitoneally administered to rats at intervals of 24 h for 2 days. The activities of lysosomal enzymes (beta-glucuronidase, beta-galactosidase, beta-glucosidase, and acid phosphatase) were significantly (p < 0.05) increased in plasma with a concomitant decline in the activities of these enzymes in heart tissue of isoprenaline-administered rats. Also, the level of lipid peroxidation was higher in heart lysosomes of isoprenaline-injected rats. Pretreatment with betaine daily for a period of 30 days to isoprenaline-induced rats prevented the changes in the activities of these lysosomal enzymes. Oral treatment with betaine (250 mg/kg body weight) to normal control rats did not show any significant effect in all the biochemical parameters studied. Thus, the results of our study show that betaine protects the lysosomal membrane against isoprenaline-induced myocardial infarction. The observed effects might be due to the free radical-scavenging and membrane-stabilizing properties of betaine.
Ganesan
Balaraman
B
Vinayaka Missions University, Ariyanoor, Salem 636308, Tamil Nadu, India. ganesancift@rediffmail.com
Anandan
Rangasamy
R
D000135:Acid Phosphatase / Q000378:metabolism; D000818:Animals; D001622:Betaine / Q000378:metabolism / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000009:adverse effects; D004789:Enzyme Activation / Q000187:drug effects* / Q000502:physiology; D006026:Glycoside Hydrolases / Q000378:metabolism; D006321:Heart; D007545:Isoproterenol / Q000009:adverse effects; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology; D008082:Lipotropic Agents / Q000494:pharmacology*; D008247:Lysosomes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D051381:Rats
D002316:Cardiotonic Agents; D008082:Lipotropic Agents; D001622:Betaine; D000135:Acid Phosphatase; D006026:Glycoside Hydrolases; D007545:Isoproterenol